Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY...
First Antiviral Drug in GlycovirologyBOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage...
LOS ANGELES, Aug. 24, 2023 (GLOBE NEWSWIRE) -- In 2010, the U.S. Congress designated September as Blood Cancer Awareness Month...
Entourage addresses market demand for affordable premium cannabis with new brand, Dime Bag® The Company announces Syndicate, a collective of exclusive...
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery,...
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President &...
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million...
Benson Provides Deep Nutraceutical Industry Business Experience to the Highly Diversified BoardMIAMI, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Smart for...
TAMPA, FL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Superlatus Inc. ('Superlatus' or the 'Company') recently merged with TRxADE HEALTH, Inc....
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a...
JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the...
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest...
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company...
HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address...
Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug....
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today...
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development...